AmerisourceBergen's CEO Discusses Q2 2012 Results - Earnings Call Transcript

AmerisourceBergen (ABC)

Q2 2012 Earnings Call

April 26, 2012 11:00 am ET

Executives

Barbara A. Brungess - Vice President of Corporate & Investor Relations

Steven H. Collis - Chief Executive Officer, President, Director and Chairman of Executive Committee

Tim G. Guttman - Acting Chief Financial Officer, Vice President and Controller

Analysts

Glen J. Santangelo - Crédit Suisse AG, Research Division

Lawrence C. Marsh - Barclays Capital, Research Division

David Larsen - Leerink Swann LLC, Research Division

Robert C. Jones - Goldman Sachs Asset Management, L.P.

Thomas Gallucci - Lazard Capital Markets LLC, Research Division

Robert M. Willoughby - BofA Merrill Lynch, Research Division

Ricky Goldwasser - Morgan Stanley, Research Division

Eric W. Coldwell - Robert W. Baird & Co. Incorporated, Research Division

Lisa C. Gill - JP Morgan Chase & Co, Research Division

Steven Valiquette - UBS Investment Bank, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbara Brungess. Please go ahead.

Barbara A. Brungess

Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Vice President, Controller and acting CFO.

During the call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.

If you liked this article you might like

How You Can Beat the Still Astronomical Prices for Prescription Drugs

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Walgreens Takes Piece of PharMerica, Quest to Dominate Healthcare Continues